Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132119
Status:
COMPLETED
Last Update Posted:
2008-05-19
First Post:
2005-08-17
Brief Title:
Nalmefene Gambling Study Study of Nalmefene HCl in the Treatment of Pathological Gambling
Sponsor:
Somaxon Pharmaceuticals
Organization:
Somaxon Pharmaceuticals
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling
Detailed Description:
Randomized double-blind placebo-controlled parallel-group multi-centered outpatient study to assess the efficacy safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None